Merck & Co (MRK)
$126.45
0.60 (0.48%)
MRK Stock Quote Delayed 30 Minutes
Should You Buy the Dow — Merck
Merck is a strong, old company with a good dividend -- it suits retirement accounts fine, but regular traders might want to keep their distance.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
320.09B
PE Ratio
140.50
EPS
0.9
Volume (Avg. Vol.)
6.79M
Day's Range
$124.91 - $126.60
52-Week Range
$99.14 - $134.63
Dividend & Yield
$2.92 (2.31%)
MRK Stock Predictions, Articles, and Merck & Co News
Vertex Scores Big With Hepatitis Drug
The company's new hepatitis C medication, Incivek, is outselling Merck's drug by 4-to-1. What's more, it's close to adding another drug to its arsenal.
Dow Jones Keeps Making Forward Progress
Alcoa, Caterpillar and Bank of America among early Wednesday's winners. IBM the only losing stock in early trading, but only by a few cents.
Big BAC Buy Leads Fine Thursday Start for Financials
Warren Buffett announces a $5 billion investment in Bank of America, and JPM, AXP also up; Dow still drops about 100 points in early trading.
No Reason to Hold Merck
As long as this big-name pharmaceutical's growth continues to stagnate, its stock price isn't going anywhere, either.
Big Pharma Cash Hoards Seem Earmarked for Opportunities in Emerging Markets
Pfizer and Merck doing little to put money toward expanding their business, and even Johnson & Johnson held back some cash in a purchase of Synthes.
Big Pharma Banking on New Cancer Treatment Approach to Boost Sales
GlaxoSmithKline, Eli Lilly and Novartis are among the companies studying epigenetics -- a new approach to fighting cancer that is already seeing some success.
Dow Jones Jettisons 300 Points Early Monday
United States credit downgrade sends Dow Jones tumbling early Monday; financials Bank of America and JP Morgan drop.
Kraft Spins Off Snacks, Wisely Bucking 2011 Buyout Boom
While the buyout frenzy still has legs, some companies, like Kraft, appear to be bucking the trend. Here's why it's not a bad move.
Merck Shares — 3 Pros, 3 Cons
Cost cuts should help the company pull off a turnaround.
Caterpillar Plods Ahead as Dow Jones Dips
Positive analyst recommendations send Caterpillar up about 2.4% in early morning trading; Dow Jones stocks Home Depot, Merck and Disney drop.
Deep-Pocket Drug Companies Poised to Reap Biosimilar Rewards
Only a few companies have the massive resources needed to get going in the upcoming "biosimilars" boom. Who will lead the charge?
Should You Buy Medco Health?
Buyout offer from Express Scripts makes this an interesting stock, but absent a bidding war, you might be better off avoiding MHS
Dow Fights Back from Brink, Thanks to Google and Oil Stocks
Facing its worst week in a year, the Dow Jones Industrial Average rose in the morning session, bolstered by strong earnings from Google (NASDAQ: GOOG) and Citi (NYSE: C), to rise about 15.40 points to over 12542, a gain of more than 15%.
Low U.S. Hiring Hounds Alcoa, CAT and Dupont
Industrials Alcoa, Caterpillar and DuPont all down about 2% in early trading; Merck a lone bright spot for Dow.
4 Health Care Stocks That Are the Prescription for a Perfect Portfolio
For the long haul, the prospects for health care stocks are promising -- and not just as a defensive play. These four picks are just what the doctor ordered.
ObamaCare Court Test a Non-event for Health Stocks
Health insurance, pharmaceutical companies' gains show confidence that ObamaCare is all but a done deal.
Techs and European Debt Woes Weigh Down Dow
Tech stocks Oracle, Micron, Microsoft, Cisco bring Dow down in early trading, and Big Pharma's Pfizer off; consumer stocks up slightly.
Fidelity Select Pharmaceutical Mutual Fund Offers Diversified Drug Play
The Fidelity Select Pharmaceutical Portfolio offers a diversified group of big pharma stocks and biotech investments that give investors a way to play the entire sector easily.
Could Legalized Pot Give Big Pharma a Much-Needed Boost?
Medical marijuana is big business where it's legalized, and if major pharmaceutical companies could get a share of the market they could see a big boost.
